OSR Health Reports Nasdaq Delisting Risk, Plans Appeal
OSR Health, a global healthcare holding company with immuno-oncology, regenerative biologics and medical device technologies, disclosed that Nasdaq issued a Staff Delisting Determination due to failure to regain the $1 minimum bid price, placing its common stock and warrants at risk of delisting from the Nasdaq Capital Market. The company said it will appeal to a Nasdaq Independent Hearings Panel and requested a hearing, with trading suspended on August 26, 2026 if the delisting proceeds. Management highlighted extraordinary mid-August trading activity—approximately 370 million shares on August 17 and 145 million on August 18—as supporting its appeal and noted the stock’s recent price range and liquidity challenges. OSR's shares have traded between about $0.25 and $1.24 in the past year, with a current level around the high 0.3s, underscoring the listing risk facing investors. Multiple outlets report the same development, emphasizing the delisting threat, the company’s appeal strategy, and ongoing concerns about liquidity and market visibility for OSR Health.
Where do you stand?
How it spread
Claim check
What each side asserts, disputes — or leaves out entirely.
Where do you land?
Whose framing of this story rings truest to you?
